[go: up one dir, main page]

PE20191541A1 - Composiciones y metodos para inhibir la accion de la arginasa - Google Patents

Composiciones y metodos para inhibir la accion de la arginasa

Info

Publication number
PE20191541A1
PE20191541A1 PE2019001311A PE2019001311A PE20191541A1 PE 20191541 A1 PE20191541 A1 PE 20191541A1 PE 2019001311 A PE2019001311 A PE 2019001311A PE 2019001311 A PE2019001311 A PE 2019001311A PE 20191541 A1 PE20191541 A1 PE 20191541A1
Authority
PE
Peru
Prior art keywords
arginase
inhibit
compositions
alkyl
action
Prior art date
Application number
PE2019001311A
Other languages
English (en)
Inventor
Eric B Sjogren
Jim Li
Zandt Michael Van
Darren Whitehouse
Lijing Chen
Roland J Billedeau
Timothy F Stanton
Jr Gunnar E Jagdmann
Lene Raunkjaer Petersen
Francesco Parlati
Matthew I Gross
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60972528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20191541(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Publication of PE20191541A1 publication Critical patent/PE20191541A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Referida a un compuesto derivado de formula (I'''), donde Rb es H, alquilo, alquenilo, alquinilo, entre otros; X es O o S; R1 y R2 son H, alquilo, alquenilo, entre otros; R3 es H, alquilo, alcoxi, SeH, entre otros; R4 es H o alquilo C1-C6. Tambien esta referida a una composicion farmaceutica. Dichos compuestos son inhibidores de arginasa y son utiles en el tratamiento del cancer
PE2019001311A 2016-12-22 2017-12-22 Composiciones y metodos para inhibir la accion de la arginasa PE20191541A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662438092P 2016-12-22 2016-12-22
US201662439614P 2016-12-28 2016-12-28
PCT/US2017/068307 WO2018119440A1 (en) 2016-12-22 2017-12-22 Compositions and methods for inhibiting arginase activity

Publications (1)

Publication Number Publication Date
PE20191541A1 true PE20191541A1 (es) 2019-10-23

Family

ID=60972528

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001311A PE20191541A1 (es) 2016-12-22 2017-12-22 Composiciones y metodos para inhibir la accion de la arginasa

Country Status (33)

Country Link
US (4) US10287303B2 (es)
EP (2) EP3842442B1 (es)
JP (2) JP7018949B2 (es)
KR (1) KR102579849B1 (es)
CN (2) CN110382508B (es)
AU (2) AU2017382405B2 (es)
BR (1) BR112019012589B1 (es)
CA (1) CA3046987A1 (es)
CL (1) CL2019001711A1 (es)
CO (1) CO2019007839A2 (es)
CR (1) CR20190339A (es)
CY (1) CY1124483T1 (es)
DK (2) DK3842442T3 (es)
EC (1) ECSP19045511A (es)
ES (2) ES2881395T3 (es)
HR (1) HRP20210848T1 (es)
HU (1) HUE054272T2 (es)
IL (2) IL292677A (es)
LT (1) LT3559009T (es)
MD (1) MD3559009T2 (es)
MX (2) MX378460B (es)
MY (1) MY197478A (es)
NZ (1) NZ754364A (es)
PE (1) PE20191541A1 (es)
PH (1) PH12019501396A1 (es)
PL (1) PL3559009T3 (es)
PT (1) PT3559009T (es)
RS (1) RS61996B1 (es)
SG (2) SG10201911240PA (es)
SI (1) SI3559009T1 (es)
SM (1) SMT202100573T1 (es)
TW (1) TWI818902B (es)
WO (1) WO2018119440A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2632927T3 (pl) 2010-10-26 2016-09-30 Boroniany jako inhibitory arginazy
TW201718581A (zh) 2015-10-19 2017-06-01 英塞特公司 作為免疫調節劑之雜環化合物
LT3377488T (lt) 2015-11-19 2023-01-10 Incyte Corporation Heterocikliniai junginiai, kaip imunomoduliatoriai
US20170174679A1 (en) 2015-12-22 2017-06-22 Incyte Corporation Heterocyclic compounds as immunomodulators
MA44860A (fr) 2016-05-06 2019-03-13 Incyte Holdings Corp Composés hétérocycliques utilisés comme immunomodulateurs
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
HUE060256T2 (hu) 2016-06-20 2023-02-28 Incyte Corp Heterociklusos vegyületek mint immunmodulátorok
US20180016260A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2941716T3 (es) 2016-08-29 2023-05-25 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
CN116115764A (zh) * 2016-12-22 2023-05-16 因赛特公司 四氢咪唑并[4,5-c]吡啶衍生物作为pd-l1内在化诱导剂
JP7303108B2 (ja) 2016-12-22 2023-07-04 インサイト・コーポレイション 免疫調節剤としての二環式複素芳香環化合物
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
WO2018119266A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Benzooxazole derivatives as immunomodulators
TWI818902B (zh) 2016-12-22 2023-10-21 美商卡利泰拉生物科技公司 用於抑制精胺酸酶活性的組合物及方法
CN108322295B (zh) 2017-01-17 2021-12-24 维沃移动通信有限公司 一种边带信息的发送方法、接收方法、发送端和接收端
US11420984B2 (en) 2018-02-17 2022-08-23 Astrazeneca Ab Arginase inhibitors and methods of use thereof
AU2019246728A1 (en) 2018-03-29 2020-08-27 Oncoarendi Therapeutics S.A. Dipeptide piperidine derivatives
ES3030010T3 (en) 2018-03-30 2025-06-26 Incyte Corp Heterocyclic compounds as immunomodulators
BR112020022936A2 (pt) 2018-05-11 2021-02-02 Incyte Corporation derivados de tetra-hidro-imidazo[4,5-c]piridina como imunomoduladores de pd-l1
SI3840837T1 (sl) 2018-08-22 2024-07-31 Astrazeneca Ab Zaviralci arginaze in postopki njihove uporabe
US12240867B2 (en) 2018-12-18 2025-03-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
DK3921033T3 (da) 2019-02-08 2023-10-16 Astrazeneca Ab Arginasehæmmere og fremgangsmåder til anvendelse deraf
CA3150434A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
CN110759843A (zh) * 2019-09-30 2020-02-07 东北师范大学 一种氟叠氮取代的四元杂环化合物的制备和应用
IL291471B2 (en) 2019-09-30 2025-04-01 Incyte Corp Pyrimido[3,2–D]pyrimidine compounds as immunomodulators
CN110734456A (zh) * 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 一种化合物及其制备方法和医药上的应用
JP2023500395A (ja) 2019-11-11 2023-01-05 インサイト・コーポレイション Ｐｄ－１／ｐｄ－ｌ１阻害剤の塩及び結晶形態
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
IL299612A (en) 2020-07-02 2023-03-01 Incyte Corp Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
WO2022016195A1 (en) 2020-07-17 2022-01-20 Incyte Corporation Processes for the preparation of arginase inhibitors and their synthetic intermediates
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
TW202233616A (zh) 2020-11-06 2022-09-01 美商英塞特公司 用於製備ｐｄ－１／ｐｄ－ｌ１抑制劑以及其鹽及結晶形式之方法
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
CN112387262B (zh) * 2020-11-10 2021-12-07 泰州学院 一种基于光催化交联蛋白的手性固定相的制备方法、手性固定相及应用
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
EP4460585A2 (en) * 2022-01-07 2024-11-13 The Trustees of Columbia University in the City of New York Inhibition of kynurenine synthesis and/or signaling to treat leukemia and myelodysplasia
CR20240447A (es) 2022-03-17 2025-01-29 Incyte Corp Compuestos de urea tricíclica como inhibidores de v617f de jak2.
WO2024086273A1 (en) 2022-10-21 2024-04-25 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2024191996A1 (en) 2023-03-13 2024-09-19 Incyte Corporation Bicyclic ureas as kinase inhibitors

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
CN1762381B (zh) 1997-07-29 2012-07-11 爱尔康实验室公司 含半乳甘露聚糖聚合物和硼酸盐的眼用组合物
AU9797998A (en) 1997-10-10 1999-05-03 Trustees Of The University Of Pennsylvania, The Compositions and methods for inhibiting arginase activity
JP2002501892A (ja) 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（−）−ビュープロピオンの薬学的使用
US20040063666A1 (en) 1998-10-09 2004-04-01 David Christianson Compositions for inhibiting arginase activity
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
ES2531552T3 (es) 2000-05-10 2015-03-17 Mayo Foundation For Medical Education And Research Anticuerpos IgM humanos con la capacidad de inducir remielinización y usos diagnósticos y terapéuticos de los mismos, particularmente en el sistema nervioso central
JP2004502948A (ja) 2000-07-06 2004-01-29 ファル　ダイアグノスティクス アルギニン化合物の検出のための方法及びキット
CA2431080A1 (en) 2003-06-02 2004-12-02 Catherine Adele O'brien Enhancement of anticancer immunity through inhibition of arginase
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
JP2007501799A (ja) 2003-08-07 2007-02-01 アラーガン、インコーポレイテッド 眼内に医薬を送達するための組成物ならびにその調製方法および使用方法
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2007005620A2 (en) 2005-07-01 2007-01-11 The Johns Hopkins University Arginase ii: a target treatment of aging heart and heart failure
WO2007095050A2 (en) 2006-02-09 2007-08-23 Incyte Corporation N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
EP2064207B1 (en) 2006-09-19 2013-11-06 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2008036643A2 (en) 2006-09-19 2008-03-27 Incyte Corporation Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US20080146624A1 (en) 2006-09-19 2008-06-19 Incyte Corporation Amidines as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
WO2008058178A1 (en) 2006-11-08 2008-05-15 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
EP2083812B1 (en) 2006-11-21 2017-04-05 Rijksuniversiteit Groningen Use of arginase inhibitors in the treatment of asthma and allergic rhinitis
DK2497470T3 (en) 2006-11-22 2015-12-07 Incyte Holdings Corp Imidazotriaziner and imidazopyrimidines as kinase inhibitors
CN101755130B (zh) 2007-07-12 2012-10-17 山洋电气株式会社 双重反转式轴流鼓风机
KR20150115959A (ko) 2007-10-12 2015-10-14 레솔빅스 파마슈티칼즈, 인코퍼레이티드 안과 질환의 치료를 위한 옥실리핀 화합물
CA2932121A1 (en) 2007-11-30 2009-06-11 Newlink Genetics Corporation Ido inhibitors
WO2009132238A2 (en) 2008-04-24 2009-10-29 Newlink Genetics Ido inhibitors
CA2722992A1 (en) 2008-05-05 2009-11-12 Schering Corporation Sequential administration of chemotherapeutic agents for treatment of cancer
HRP20141094T1 (hr) 2008-07-08 2015-01-16 Incyte Corporation 1,2,5-oksadiazoli kao inhibitori indolamin 2,3-dioksigenaze
US20100189644A1 (en) 2009-01-26 2010-07-29 The Trustees Of The University Of Pennsylvania Arginase inhibitors and methods of use
AU2010339508B2 (en) 2009-12-31 2016-02-04 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
EP2547366A4 (en) 2010-03-18 2013-08-07 Univ Colorado State Res Found SUPPRESSOR CELL HEMMER OBTAINED FROM MYELOID CELLS
WO2011133653A1 (en) 2010-04-22 2011-10-27 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
JP5266430B2 (ja) 2010-04-24 2013-08-21 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 金属酵素阻害化合物
US8680136B2 (en) * 2010-08-10 2014-03-25 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
AU2011295440B2 (en) 2010-08-27 2015-06-11 Merck Patent Gmbh Triazolopyrazine derivatives
PL2632927T3 (pl) 2010-10-26 2016-09-30 Boroniany jako inhibitory arginazy
AU2011320565A1 (en) 2010-10-28 2013-05-23 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
KR20180039185A (ko) 2010-11-13 2018-04-17 이노크린 파마슈티컬즈, 인크. 금속효소 억제제 화합물
EA201390876A1 (ru) 2010-12-13 2013-12-30 Вайамет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
WO2012091757A1 (en) 2010-12-31 2012-07-05 Corridor Pharmaceuticals, Inc. Arginase inhibitors and methods of use thereof
NO2694640T3 (es) 2011-04-15 2018-03-17
KR20180095109A (ko) 2011-06-19 2018-08-24 비아멧 파마슈티컬즈(엔씨), 인코포레이티드 금속효소 억제제 화합물
CA2839769A1 (en) 2011-06-19 2012-12-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
WO2012177725A1 (en) 2011-06-23 2012-12-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
US9150527B2 (en) 2011-08-30 2015-10-06 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN104244932B (zh) 2011-10-19 2017-02-22 马尔斯公司 精氨酸酶抑制剂和其治疗应用
CA2852936A1 (en) 2011-10-20 2013-04-25 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
WO2013090210A1 (en) 2011-12-11 2013-06-20 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
EA026209B1 (ru) 2012-01-20 2017-03-31 Ваймет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
AU2012367141B2 (en) 2012-01-28 2016-12-22 Merck Patent Gmbh Triazolo[4,5-d]pyrimidine derivatives
EP2817310B1 (en) 2012-02-21 2018-03-21 Merck Patent GmbH 8-substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrazines as syk tryrosine kinase inhibitors and gcn2 serin kinase inhibitors
CN104254531B (zh) 2012-02-21 2017-05-03 默克专利股份公司 环状二氨基嘧啶衍生物
US20150051202A1 (en) 2012-03-07 2015-02-19 Merck Patent Gmbh Triazolopyrazine derivatives
WO2013158262A1 (en) 2012-04-18 2013-10-24 Mars, Incorporated Ring constrained analogs as arginase inhibitors
CA2881279C (en) 2012-08-07 2020-07-07 Merck Patent Gmbh Pyridopyrimidine derivatives as protein kinase inhibitors
US20150246898A1 (en) 2012-09-12 2015-09-03 Dow Agrosciences Llc Metalloenzyme inhibitor compounds
CN111329989A (zh) 2012-11-02 2020-06-26 药品循环有限责任公司 Tec家族激酶抑制剂辅助疗法
WO2014117090A1 (en) 2013-01-28 2014-07-31 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
US9617266B2 (en) 2013-03-05 2017-04-11 Merck Patent Gmbh Imidazopyrimidine derivatives
AU2014224975B2 (en) 2013-03-05 2017-09-14 Merck Patent Gmbh Triazolo(4,5-d)pyrimidine derivatives for the treatment of diseases such as cancer
KR20150126623A (ko) 2013-03-14 2015-11-12 뉴링크 제네틱스 코퍼레이션 트립토판 대사로 인한 면역억제의 억제제로서의 삼환식 화합물
BR112015022575B1 (pt) 2013-03-14 2022-03-22 Curadev Pharma Private Ltd Composto, pró-drogas de um composto, composição e método para preparar um composto
WO2014141110A2 (en) 2013-03-14 2014-09-18 Curadev Pharma Pvt. Ltd. Aminonitriles as kynurenine pathway inhibitors
JP6313415B2 (ja) 2013-03-15 2018-04-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｉｄｏ阻害剤
HRP20180971T1 (hr) 2013-03-15 2018-08-10 Bristol-Myers Squibb Company Inhibitori indolamin 2,3-dioksigenaze (ido)
CA2911259A1 (en) 2013-05-06 2014-11-13 Merck Patent Gmbh Macrocycles as kinase inhibitors
HK1223093A1 (zh) 2013-05-28 2017-07-21 Viamet Pharmaceuticals (NC), Inc. 杀真菌组合物
CN105473550B (zh) 2013-07-01 2019-02-15 百时美施贵宝公司 Ido抑制剂
MX366875B (es) 2013-07-11 2019-07-29 Bristol Myers Squibb Co Inhibidores de indoleamina 2,3-dioxigenasa (ido).
WO2015017402A1 (en) 2013-07-29 2015-02-05 Board Of Regents Of The University Of Nebraska Compositions and methods for the treatment of biofilm infections
CA2921199A1 (en) 2013-08-27 2015-03-05 Bristol-Myers Squibb Company Ido inhibitors
CA2927794A1 (en) 2013-10-25 2015-04-30 Pharmacyclics Llc Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
US9321755B2 (en) 2013-11-08 2016-04-26 Incyte Corporation Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor
SG10201806297VA (en) 2014-02-04 2018-08-30 Incyte Corp Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
WO2015160664A1 (en) 2014-04-15 2015-10-22 Dow Agrosciences Llc Metalloenzyme inhibitor compounds as fungicides
CN106231901A (zh) 2014-04-15 2016-12-14 美国陶氏益农公司 作为杀真菌剂的金属酶抑制剂化合物
BR112016028255A2 (pt) 2014-06-06 2017-08-22 Flexus Biosciences Inc agentes imunorreguladores
TW201619133A (zh) 2014-08-21 2016-06-01 裘拉德製藥私人有限公司 新穎亞氨腈（ｉｍｉｎｏｎｉｔｒｉｌｅ）衍生物
EP3189054B1 (en) 2014-09-05 2019-07-24 Merck Patent GmbH (1-fluoro-cyclohex-1-yl)-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer
CN105879030A (zh) 2014-09-30 2016-08-24 复旦大学 治疗肿瘤的增效药物复合物及其制备方法
GB201417369D0 (en) 2014-10-01 2014-11-12 Redx Pharma Ltd Compounds
WO2016057986A1 (en) 2014-10-10 2016-04-14 The Trustees Of Columbia University In The City Of New York Tandem epitope constructs for presentation of cd4 and cd8 epitopes and uses thereof
GB201418300D0 (en) 2014-10-15 2014-11-26 Redx Pharma Ltd Compounds
BR112017008809A2 (pt) 2014-11-05 2017-12-19 Flexus Biosciences Inc agentes imunorreguladores
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
UY36391A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
WO2016153078A1 (en) 2015-03-20 2016-09-29 Opiyo Sammy Oyoo Use of suramin and arginase inhibitors in malignant neoplasia
CN107743481A (zh) 2015-04-03 2018-02-27 百时美施贵宝公司 用于治疗癌症的吲哚胺2,3‑双加氧酶抑制剂
EP3626720A1 (en) 2015-04-03 2020-03-25 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
TW201705955A (zh) 2015-05-14 2017-02-16 輝瑞大藥廠 包含吡咯啶－２，５－二酮ｉｄｏ１抑制劑及抗－ｐｄ１／抗－ｐｄ－ｌ１抗體之組合療法
WO2016196890A1 (en) 2015-06-04 2016-12-08 Vtv Therapeutics Llc Inhibitors of hexokinase and methods of use thereof
EP3313410A4 (en) 2015-06-23 2019-01-02 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
NZ742742A (en) 2015-10-30 2023-04-28 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
TWI818902B (zh) 2016-12-22 2023-10-21 美商卡利泰拉生物科技公司 用於抑制精胺酸酶活性的組合物及方法
MX2019013533A (es) 2017-05-12 2020-08-03 Calithera Biosciences Inc Metodo para preparar (3r,4s)-3-acetamido-4-alil-n-(terc-butil)pirr olidina-3-carboxamida.

Also Published As

Publication number Publication date
SMT202100573T1 (it) 2021-11-12
US12054501B2 (en) 2024-08-06
ES2970715T3 (es) 2024-05-30
US20180222926A1 (en) 2018-08-09
PT3559009T (pt) 2021-05-04
HRP20210848T1 (hr) 2021-07-09
IL267532A (en) 2019-08-29
EP3842442A1 (en) 2021-06-30
US11021495B2 (en) 2021-06-01
RS61996B1 (sr) 2021-07-30
AU2022201072A1 (en) 2022-03-10
CL2019001711A1 (es) 2020-01-17
NZ754364A (en) 2023-04-28
JP2020514271A (ja) 2020-05-21
BR112019012589A2 (pt) 2019-11-19
IL292677A (en) 2022-07-01
KR20190119579A (ko) 2019-10-22
DK3842442T3 (da) 2024-02-05
MX2020013649A (es) 2021-02-26
MX378460B (es) 2025-03-10
EP3842442B1 (en) 2023-11-01
JP2022066199A (ja) 2022-04-28
US20190330244A1 (en) 2019-10-31
CN114989205A (zh) 2022-09-02
LT3559009T (lt) 2021-06-25
CN110382508A (zh) 2019-10-25
AU2017382405A1 (en) 2019-06-27
WO2018119440A1 (en) 2018-06-28
CN110382508B (zh) 2022-08-02
TWI818902B (zh) 2023-10-21
CA3046987A1 (en) 2018-06-28
HUE054272T2 (hu) 2021-09-28
PL3559009T3 (pl) 2021-10-25
MD3559009T2 (ro) 2021-07-31
MY197478A (en) 2023-06-19
ECSP19045511A (es) 2019-10-31
CR20190339A (es) 2020-01-10
BR112019012589B1 (pt) 2022-11-29
SI3559009T1 (sl) 2021-08-31
US20200339607A1 (en) 2020-10-29
DK3559009T3 (da) 2021-05-03
SG10201911243WA (en) 2020-02-27
SG10201911240PA (en) 2020-02-27
ES2881395T3 (es) 2021-11-29
EP3559009A1 (en) 2019-10-30
US20210261573A1 (en) 2021-08-26
US10597411B2 (en) 2020-03-24
JP7018949B2 (ja) 2022-02-14
PH12019501396A1 (en) 2019-12-02
MX2019007471A (es) 2019-11-05
TW201828948A (zh) 2018-08-16
IL267532B (en) 2022-06-01
KR102579849B1 (ko) 2023-09-18
EP3559009B1 (en) 2021-04-07
CO2019007839A2 (es) 2019-10-21
AU2017382405B2 (en) 2021-12-16
CY1124483T1 (el) 2022-07-22
US10287303B2 (en) 2019-05-14

Similar Documents

Publication Publication Date Title
PE20191541A1 (es) Composiciones y metodos para inhibir la accion de la arginasa
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
PE20211782A1 (es) Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos
EA201991399A1 (ru) Аминотриазолопиридиновые соединения и их применение в лечении рака
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
PE20170247A1 (es) Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1
CO2019003482A2 (es) Compuestos derivados de ciclobutano o azetidina 1,3 disustituidos como inhibidores de la prostaglandina d sintasa hematopoyética
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
PE20142098A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
PE20171241A1 (es) Terapias de combinacion para el tratamiento de canceres
MX385731B (es) Compuestos de biaril-monobactam y métodos de uso de los mismos para el tratamiento de infecciones bacterianas.
PE20150400A1 (es) Benzamidas n-sustituidas y su uso en el tratamiento del dolor
MX2016016528A (es) Inhibidores de fosfatidilinositol 3-quinasa.
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
MX2021003843A (es) Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer.
PE20161236A1 (es) Compuesto de triazina y su uso para fines medicos
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
PE20170148A1 (es) Compuestos de 1,3, 4-tiadiazol y uso de los mismos para el tratamiento del cancer
PE20171335A1 (es) Inhibidores de gingipaina de lisina
MX390051B (es) Antagonistas de ep4.
MX2018013164A (es) Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa.
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos